Involvement of CYP2D6 activity in the N-oxidation of procainamide in man

Pharmacogenetics

Volumn 9, Issue 6, 1999, Pages 683-696

  Lessard, Étienne ^a,b   Hamelin, Bettina A ^a,b   Labbé, Line ^a,b   O'Hara, Gilles ^a,b   Bélanger, Pierre Maxime ^b   Turgeon, Jacques ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

CYP2D6; Cytochrome P450; N oxidation; Procainamide

Indexed keywords

CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; PROCAINAMIDE; QUINIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; LUPUS ERYTHEMATOSUS; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0033407126     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-199912000-00003     Document Type: Article

References (67)

1. Alarcon-Segovia D. Drug-induced antinuclear antibodies and lupus syndromes. Drugs 1976; 12:69-77.
2. Bigger JT Jr, Heissenbuttel RH. The use of procainamide and lidocaine in the treatment of cardiac arrhythmias. Prog Cardiovasc Dis 1969; 11:515-534.
3. Bowles SK, Cardozo L, Edwards DJ. Quinidine does not alter antipyrine metabolism. J Clin Pharmacol 1990; 30:267-271.
4. Breimer DD. Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin Pharmacokinet 1983; 12:779-784.
5. Broly F, Libersa C, L'Hermitte M, Bechtel P, Dupuis B. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 1989; 28:29-36.
6. Broly F, Vandamme N, Caron J, Libersa C, L'Hermitte M. Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine. Life Sci 1991; 48:PL123-PL128.
7. Brosen K, Gram LF. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Invest 1989; 37:155-160.
8. Brosen K, Gram LF, Haghfelt T, Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 1987; 60:312-314.
9. Brosen K, Davidsen F, Gram LF. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Br J Clin Pharmacol 1990; 29:248-253.
10. Budinsky RA, Roberts SM, Coats EA, Adams L, Hess EV. The formation of procainamide hydroxylamine by rat and human liver microsomes. Drug Metab Disp 1987; 15:37-43.
11. Caporaso NE, Shaw GL. Clinical implications of the competitive inhibition of the debrisoquine-metabolizing isozyme by quinidine. Arch Intern Med 1991; 151:1985-1992.
12. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6:539-546.
13. Christoff PB, Conti DR, Naylor C, Jusko WJ. Procainamide disposition in obesity. Drug Intell Clin Pharm 1983; 17:516-522.
14. Coutts RT, Su P, Baker GB. Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Methods 1994; 31:177-186.
15. Coyle JD, Boudoulas H, MacKichan JJ, Lima JJ. Concentration-dependent clearance of procainamide in normal subjects. Biopharm Drug Dispos 1985; 6:159-165.
16. Deloménie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996; 6:177-185.
17. DuSouich P, Erill S, Patterns of acetylation of procainamide and procainamide derived p-aminobenzoic acid in man. Eur J Clin Invest 1976; 10:283-287.
18. East T, Dye D. Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1985; 338:99-112.
19. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism. Clinical aspects. Pharmacol Ther 1990; 46:377-394.
20. Evert B, Griese EU, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedebergs Arch Pharmacol 1994a; 350:434-439.
21. 1795 in exon 3 generates a premature stop codon. Pharmacogenetics 1994b; 4:271-274.
22. Freeman RW, Woosley RL. Oates JA, Harbison RL. Evidence for the biotransformation of procainamide to a reactive metabolite. Toxicol Appl Pharmacol 1979; 50:9-16.
23. Freeman RW, Uetrecht JP, Woosley RL, Oates JA, Harbison RD. Covalent binding of procainamide in vitro and in vivo to hepatic protein in mice. Drug Metab Disp 1981; 9:188-192.
24. Frislid K, Berg M, Hansteen V. Comparison of the acetylation of procainamide and sulfamidine in man. Eur J Clin Invest 1976; 9:433-438.
25. Funck-Brentano C, Kroemer HK, Pavlou H, Woosley RL, Roden DM. Genetically determined interaction between propafenone and low close quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol 1989a; 27:435-444.
26. Funck-Brentano C, Light RT, Lineberry MD, Wright GM, Roden DM, Woosley RL. Pharmacokinetic and pharmacodynamic interaction of N-acetylprocainamide and procainamide in humans. J Cardiovasc Pharmacol 1989b; 14:364-373.
27. Funck-Brentano C, Turgeon J, Woosley RL, Roden DM. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics: influence of genetic polymorphism. J Pharmacol Exp Ther 1989c; 249:134-142.
28. Gibson TP, Matusik J, Matusik E. Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype. Clin Pharmacol Ther 1974; 17:395-399.
29. Gibson TP, Atkinson AJ Jr, Matusik E. Kinetics of procainamide an N-acetylprocainamide in renal failure. Kidney Int 1977; 12:422-429.
30. Griesemer DA. Procainamide-induced lupus. Johns Hopkins Med J 1976; 138:289-295.
31. Hamelin BA, Turgeon J, Vallée F, Bélanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not of sertraline is altered in poor metabolizers of debrisoquine. Clin Pharmacol Ther 1996; 60:512-521.
32. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336:529-532.
33. Hou ZY, Pickle LW, Meyer PS, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 1991; 49:410-419.
34. Hughes B, Dyer JE, Sehwartz AB. Increased procainamide plasma concentrations caused by quinidine: a new drug interaction. Am Heart J 1987; 114:908-909.
35. Interian A Jr, Zaman L, Velez-Robinson E, Kozlovskis P, Castellanos A, Myerburg RJ. Paired comparisons of efficacy of intravenous and oral procainamide in patients with inducible sustained ventricular tachyarrhythmias. J Am Coll Cardiol 1991; 17:1581-1586.
36. Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994; 266:810-813.
37. Karlsson E, Molin L. Polymorphic acetylation of procainamide in healthy subjects. Acta Med Scand 1975; 197:299-302.
38. Koch-Weser J. Antiarrhythmic prophylaxis in ambulatory patients with coronary heart disease. Arch Intern Med 1972; 129:763-772.
39. Koch-Weser J, Klein SW. Procainamide dosage schedules, plasma concentrations, and clinical effects. JAMA 1971; 215:1454-1460.
40. Lessard E, Fortin A, Bélanger PM, Beaune P, Hamelin BA, Turgeon J. Role of CYP2D6 in the N-hydroxylation of procainamide. Pharmacogenetics 1997; 7:381-390.
41. Lessard E, Fortin A, Coquet A, Bélanger PM, Hamelin BA, Turgeon J. Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study. J Chromatogr Sci 1998; 36:49-54.
42. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2:584-586.
43. Mongey AB, Donovan-Brand R, Thomas TJ, Adams LE, Hess EV. Serologic evaluation of patients receiving procainamide. Arthritis Rheum 1992; 35:219-223.
44. Nielsen MD, Brosen K, Gram LF. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol 1990; 29:299-304.
45. Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1984; 34:73-80.
46. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 1988; 247:242-247.
47. Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17:102-105.
48. Reidenberg MM, Drayer DE, Levy M, Warner H. Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 1975; 172:722-730.
49. Roberts SM, Adams LE, Donovan-Brand RJ, Budinsky RA, Skoulis NP, Zimmer HW, Hess EV. Procainamide hydroxilamine lymphocyte toxicity in the rat: evidence for participation by hemoglobin. Int J Pharmacol 1989; 11:419-427.
50. Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith R, Oates JA, Woosley RL. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol 1980; 46:463-468.
51. Ruo TI, Morita Y, Atkinson AJ Jr, Henthorn T, Thenot JP. Identification of desethyl procainamide in patients: a new metabolite of procainamide. J Pharmacol Exp Ther 1981; 216:357-362.
52. Schellens JHM, Ghabrial H, van der Wart HHF, Bakker EN, Wilkinson GR, Breimer DD. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clin Pharmacol Ther 1991; 50:520-528.
53. Sebaldt RJ, Kreeft JH. Efficient pharmacokinetic modeling of complex clinical dosing regimens: the universal elementary dosing regimen and computer algorithm EDFAST. J Pharm Sci 1987; 76:93-100.
54. Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies D. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolisers of debrisoquine. Br J Clin Pharmacol 1986; 22:739-743.
55. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5:215-223.
56. Steiner E, Dumont E, Spina E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther 1988; 43:577-581.
57. Turgeon J, Pavlou HN, Wong W, Funck-Brentano C, Roden DM. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. J Pharmacol Exp Ther 1990; 255:642-649.
58. Uetrecht JP. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther 1985; 232:420-425.
59. Uetrecht JP, Woosley RL. Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet 1981; 6:118-134.
60. Uetrecht JP, Freeman RW, Woosley RL. The implications of procainamide metabolism to its induction of lupus. Arthritis Rheum 1981; 24:994-999.
61. Uetrecht JP, Sweetman BJ, Woosley RL, Oates JA. Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes. Drug Metab Disp 1984; 12:77-81.
62. Uetrecht JP, Zahid N, Rubin RL. Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytes. Chem Res Toxical 1988; 1:74.
63. von Schmiedeberg S, Goebel C, Gleichmann E, Uetrecht J. Neutrophils and drug metabolism. Science 1995; 268:585-1586.
64. Weinstein A. Drug-induced lupus erythematosus. Prog Clin Immunol 1980; 4:1-21.
65. Wheeler JF, Adams LE, Mongey AB, Roberts SM, Heineman WR, Hess EV. Determination of metabolically derived nitroprocainamide in the urine of procainamide-dosed humans and rats by liquid chromatography with electrochemical detection. Drug Metab Disp 1991; 19:691-695.
66. Woosley RL, Drayer DE, Reidenberg MM, Nies AS. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978; 298:1157-1159.
67. Xhou HH, Anthony LB, Roden DM, Wood AJJ. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther 1990; 47:686-693.